A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK
<p>Abstract</p> <p>Background</p> <p>A live-attenuated vaccine aimed at preventing herpes zoster (HZ) and its main complication, post-herpetic neuralgia (PHN) is available in Europe for immunocompetent adults aged 50 years and more. The study objective is to assess the...
Main Authors: | Martin Monique, Remy Vanessa, Moore Lee, Beillat Maud, McGuire Alistair |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-04-01
|
Series: | Cost Effectiveness and Resource Allocation |
Online Access: | http://www.resource-allocation.com/content/8/1/7 |
Similar Items
-
The impact of herpes zoster and post-herpetic neuralgia on quality-of-life
by: Schmader Kenneth E, et al.
Published: (2010-06-01) -
The cost-effectiveness of introducing a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in elderly Danes
by: Lone Bilde, et al.
Published: (2016-12-01) -
Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: A retrospective, population-based study
by: Serradell Laurence, et al.
Published: (2010-08-01) -
Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study.
by: Sinéad M Langan, et al.
Published: (2013-01-01) -
Herpes zoster in pregnancy leading to keloids and post herpetic neuralgia: A double whammy?
by: Shyam B Verma, et al.
Published: (2013-01-01)